Gerum S, Jensen AD, Roeder F. Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review. World J Gastrointest Oncol 2019; 11(5): 367-376 [PMID: 31139307 DOI: 10.4251/wjgo.v11.i5.367]
Corresponding Author of This Article
Falk Roeder, MD, Associate Professor, Department of Radiotherapy and Radiation Oncology, Paracelsus Medical University, Landeskrankenhaus Salzburg, Müllner Hauptstrasse 48, Salzburg, 5020, Austria. falk.roeder@t-online.de
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. May 15, 2019; 11(5): 367-376 Published online May 15, 2019. doi: 10.4251/wjgo.v11.i5.367
Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review
Sabine Gerum, Alexandra D Jensen, Falk Roeder
Sabine Gerum, Department of Radiation Oncology, University Hospital LMU Munich, Munich, 81377, Germany
Alexandra D Jensen, Department of Radiation Oncology, University Hospital Gießen and Marburg, Marburg, 35043, Germany
Falk Roeder, CCU Molecular Radiation Oncology, German Cancer Research Center, Heidelberg, 74626, Germany
Falk Roeder, Department of Radiotherapy and Radiation Oncology, Paracelsus Medical University, Salzburg, 5020, Austria
Author contributions: Gerum S participated in drafting the manuscript, generated the figures and assisted in literature research; Jensen AD drafted the parts dealing with particle therapy and critically reviewed the manuscript, Roeder F drafted the manuscript, generated the tables and performed the literature research.
Conflict-of-interest statement: All authors declare no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Falk Roeder, MD, Associate Professor, Department of Radiotherapy and Radiation Oncology, Paracelsus Medical University, Landeskrankenhaus Salzburg, Müllner Hauptstrasse 48, Salzburg, 5020, Austria. falk.roeder@t-online.de
Telephone: +43-5-725527101 Fax: +43-5-725527299
Received: January 16, 2019 Peer-review started: January 17, 2019 First decision: January 26, 2019 Revised: March 14, 2019 Accepted: March 27, 2019 Article in press: March 28, 2019 Published online: May 15, 2019 Processing time: 120 Days and 0.4 Hours
Abstract
Stereotactic body radiation therapy (SBRT) is an emerging treatment for hepatocellular carcinoma. This technique results in excellent local control rates with favorable toxicity profile despite being predominantly used in heavily pretreated patients or those unsuitable for other local therapies. SBRT may be used as a sole treatment or in combination with other local therapies as well as a bridging strategy for patient awaiting liver transplants. This brief review describes current practice of SBRT with respect to radiation technique, patient selection and treatment concepts. It summarizes available evidence from retro- and prospective studies evaluating SBRT alone, SBRT in combination with other treatments and SBRT compared to other local treatment approaches.
Core tip: Stereotactic body radiation therapy (SBRT) is an emerging treatment for hepatocellular carcinoma. It may be used as a sole treatment or in combination with other local therapies as well as a bridging strategy for patient awaiting transplants and results in excellent local control rates with low toxicity. This mini-review describes current concepts of SBRT and summarizes the available evidence evaluating SBRT alone, SBRT in combination with other treatments and SBRT compared to other local treatment approaches.
